Determining Heart Attack in the ER
The research team decided to conduct a clinical trial to assess the new technique's effectiveness in determining whether a patient has had a heart attack. They enrolled 1,320 patients who visited the emergency department with suspected acute myocardial infarction (MI) and applied the high-sensitivity cardiac troponin T 1-hour algorithm to blood samples.
Acute MI is a common cause of death and disability around the world. Early diagnosis of the condition is critical for treatment and survival. Cardiac troponins (T and I) are currently the gold standard for definitive acute MI diagnosis due to their high sensitivity and specificity for detection of myocardial cell injury. However, troponin is undetectable by current tests in peripheral blood within 3 to 4 hours after onset of chest pain in acute MI.
"Introducing the high-sensitivity cardiac troponin T 1-hour algorithm into clinical practice would represent a profound change and it is therefore important to determine if it works in a large patient group," explains the study's lead author Dr. Tobias Reichlin, Department of Cardiology and Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland.
With the 1-hour algorithm, Dr. Reichlin and colleagues were able to determine that 786 (60 percent) of patients did not have an acute MI ("rule out"), 216 (16 percent) were "rule in" and 318 (24 percent) were to be observed because results were not conclusive.
"This rapid strategy incorporating high-sensitivity cardiac troponin T baseline values and absolute changes after the first hour substantially accelerates the management of patients with suspected acute MI by allowing safe rule-out as well as accurate rule-in of acute MI in 3 out of 4 patients," Dr. Reichlin's team concludes. The findings are reported in CMAJ (Canadian Medical Association Journal).
Source: Canadian Medical Association Journal
Image Credit: Google Images
Published on : Thu, 16 Apr 2015
Print as PDF
Get an complete overview of your POCT setup - from one dashboard Your point-of-care-testing setup probably involves many different types of devices from various manufacturers. Radiometer's AQURE point-of-care management system can give you an overview...
The HAMILTON-T1 combines for the first time the functionality of a fully featured intensive care unit ventilator with the compactness and ruggedness required for transport. This is why the HAMILTON-T1 enables you to provide optimal ventilation therapy...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...